Gene Editing

Another stark warning over CRISPR/Cas9’s potential to do lasting harm dents share prices

Birthing anything new in biotech can be extremely hard. But gene-editing may win the prize for unexpected hurdles.

Fast on the heels of scary reports that a popular gene editing tech could trigger an increased  cancer risk, another group of scientists is ringing a very loud alarm bell in Nature today warning that CRISPR/Cas9 editing triggers havoc in DNA that could well prove harmful to people.

Michael Kosicki, Kärt Tomberg and Allan Bradley delivered their warning in unmistakable terms:

In the clinical context of editing many billions of cells, the multitude of different mutations generated makes it likely that one or more edited cells in each protocol would be endowed with an important pathogenic lesion. Such lesions may constitute a first carcinogenic ‘hit’ in stem cells and progenitors, which have a long replicative lifespan and may become neoplastic with time.

“We found that changes in the DNA have been seriously underestimated before now,” Bradley, a professor at Britain’s Wellcome Sanger Institute, told Reuters. And anyone thinking of doing this in humans should proceed with great caution.

That’s not what the gene-editing companies wanted to hear, especially after earlier warnings kicked their stock prices lower. Their losses on Nasdaq are growing today.

Editas $EDIT is down 5% in the mid-afternoon. CRISPR Therapeutics $CRSP is down 7%. And Intellia $NTLA is down 7%.

Intellia, for one, quickly batted back against the report. In a statement, the biotech says that nothing in this report is new or particularly alarming, as far as it’s concerned. These deletions aren’t new, it’s unlikely to be specific to CRISPR/Cas9 (with applications to other gene editing technologies) and won’t “significantly impact the path forward for CRISPR-based therapeutics.”

Image: Shutterstock

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->